PatientGPT from Semalytix Will Replace Six Months of Evidence & Insight Generation in Life Science with Seconds

First Patient-Centric Language Model Approach Revolutionizes Life Science

• Real-time patient experience data from 100 million sources in 26 languages
• A specifically designed Large Language Model trained on global patient experience data for Life Sciences
• PatientGPT will replace 6 months of real-world research with seconds
• A milestone for patient-focused drug development

Bielefeld, July 11, 2023 | A new era in drug development begins with the announcement of PatientGPT. Thanks to the interplay between supervised Machine Learning and Large-Language Models, PatientGPT will provide critical accuracy - a milestone and a must-have in Life Sciences. Effects and value estimates of medications based on millions of patient experiences can be analyzed and interpreted in seconds, a task that would otherwise require up to 6 months of work. Additionally, Europe benefits from strong safety measures and anonymization guidelines for sensitive patient data.

For nearly 8 years, Bielefeld-based life science startup Semalytix has been transforming the €1.25 trillion pharmaceutical industry, constantly delivering advances and key technologies made-in-Bielefeld. With the world's first functional prototype of a LLM that answers questions on supervised patient experiences, the company from East Westphalia takes another leap forward. "We can not only analyze but also precisely query the effects of any medication based on patient experiences and unmet needs worldwide, down to the smallest detail," says co-founder and Chief Product Officer, Janik Jaskolski. "By the end of the year, we will have over 50 million patient data points in our patient experience data archive, which our own LLM solution will be tuned with. This allows us to gain exact insights into how people live with diseases and generate crucial new knowledge for patient-focused drug development," states the cognitive computer scientist Janik Jaskolski.

Pushing the boundaries further

"PatientGPT truly unlocks the huge potential of patient experience data that will help shape new therapies and authentically and continuously answer what patients need most," says Prof. Dr. Philipp Cimiano, co-founder and Chief Technology Officer. The most popular example from recent history is the accidental invention of the potent drug Viagra in 1998, which was originally a side effect of the tested hypertension medication and repurposed based on patient experiences. Thanks to modern technologies, this kind of learning can now be amplified. "With access to over 100 million sources in 26 different languages, and combining patient experiences from around the world over the past 10 years, the treasure of global patient knowledge already resides in our Pharos platform," says Janik Jaskolski.

That knowledge is now made accessible thanks to the synergy between the data that has been enriched with supervised machine learning and the incredible ease of interaction of Large-Language Models. The difference with PatientGPT is that its answers are exclusively based on data that has already been analyzed by Semalytix’s extensive supervised AI framework. This makes responses more accurate, less prone to hallucinations, and even allows users to fact-check on-the-fly. Additionally, the prototype can access real-time data. "Billions of pieces of information about patient-centered experiences reveal entirely new opportunities for therapies and medication," says Janik Jaskolski. "What experiences have patients across the globe had with medication X, condition Y, and what needs to be done to improve their quality-of-life? PatientGPT summarizes thousands of patient voices and will give you an answer to this question, again and again," Janik continues.

The new piece to the puzzle, PatientGPT, perfectly fits into the AI-based research technology that already produces insights & evidence for diseases such as depression, breast cancer, and diabetes. "We want to dramatically accelerate the speed of therapy development and improve how well new drugs match patients’ burdens. We contribute by making the global patient experience as accessible as possible in a compliant and ethical way." says Chief Product Officer, Janik. The many case studies, innovation projects, and publications already demonstrate the upcoming AI-driven medical revolution and underline the important work of the pioneering team from Bielefeld. Semalytix's customers include many of the top 20 pharmaceutical companies worldwide.

About Semalytix:

Semalytix is a Bielefeld-based AI-technology startup that identifies unmet patient needs and generates a deep understanding of how people experience diseases. As the world‘s first technology company, Semalytix is committed to enhancing patient results, and develops cutting-edge technologies that leverage the power of patient experience data to drive informed decision-making within the healthcare industry. Semalytix was founded in 2015 by managing directors Janik Jaskolski, Philipp Cimiano, and Matthias Hartung and currently employs 25 employees.

Press contact:
Shima Reza
Global Marketing Director
shima.reza@semalytix.com